Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.

Autor: Lee GJ; Department of Internal Medicine, Bucheon St Mary's Hospital, The Catholic University School of Medicine, Bucheon, Korea., Min JW, Seo MW, Lee MY, Jin JY
Jazyk: angličtina
Zdroj: The journal of obstetrics and gynaecology research [J Obstet Gynaecol Res] 2014 Jan; Vol. 40 (1), pp. 297-300. Date of Electronic Publication: 2013 Sep 19.
DOI: 10.1111/jog.12161
Abstrakt: The efficacy of second-line chemotherapy for relapsed primary peritoneal serous carcinoma has been numerously reported, but reports on durable response after second-line therapy have been rare. We report the case of a 66-year-old woman with relapsed primary peritoneal serous carcinoma who showed durable response after just one cycle of second-line belotecan-based therapy. The response might be a complete pathologic remission. Considering the fact that our patient suffered from neutropenic sepsis during her treatment, we concluded that belotecan-based chemotherapy could be a good option for second-line chemotherapy in some selected patients, so patient selection should be carefully performed due to the toxicity of belotecan.
(© 2013 The Authors. Journal of Obstetrics and Gynaecology Research © 2013 Japan Society of Obstetrics and Gynecology.)
Databáze: MEDLINE
Externí odkaz: